CD274 and acute myeloid leukemia: Hypomethylating agents (HMAs) have been shown to affect the immune system, and a combination of HMA with PD-1/PD-L1 inhibition has been evaluated in AML in several studies, with a subset of patients found to respond to the combination regimen (Daver et al., 2019).